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Abstract 20 
The nucleoside CAM-263, with an unusual tricyclic carbohydrate moiety, specifically inhibits HIV-1 replication while being 
inactive against HIV-2 or other (retro) viruses. In an attempt to increase the inhibitory efficacy against HIV -1, and to further 
explore the structural features required for anti-HIV-1 activity, different types of modifications have been carried out on this 
prototype compound. These include substitution of the  the ethoxy group at the C-4” position by alkoxy groups of different 
length, ramification, conformational freedom or functionalization. In addition, the 4”-ethoxy group has been removed or 25 
substituted by other functional groups. Next, we studied the role of the tert-butyldimethylsilyl (TBDMS) group at the 2’ position 
by preparing the corresponding 2’-deprotected derivative or by replacing it by other silyl (tert-hexyldimethylsilyl) or acetyl 
moiety. Finally, the thymine of the prototype compound has been replaced by N-methylthymine, uracil or SPh. Some of these 
compounds showed moderate and specific anti-HIV-1 activity. 
Introduction 30 
In the last few years the design and synthesis of nucleosides with bicyclic carbohydrate moieties have attracted considerable  
attention to restrict the conformational flexibility of the nucleoside in to determined conformations which was ideal for nucleic 
acid recognition.1 On the other hand, a great diversity of bicyclic nucleosides have been synthesized in order to identify 
conformational preferences of some receptors and enzymes involved in the metabolism or polymerization of nucleosides and to 
study the interaction of such compounds with their enzymatic targets.2 Some bicyclic nucleosides have shown to inhibit 35 
moderately HIV replication3 although none of them are specific for HIV-1.  
 In order to induce further conformational restriction in the bicyclic nucleosides the in troduction of additional bridges 
generating tricyclic nucleosides was also undertaken.4   However, no biological evaluation against HIV of these compounds have 
been reported so far.  
 In an earlier work, we described the efficient transformation (one-step, high yields, and easy purifications) of the nucleoside 40 
CAM-261 (Figure 1)5 into bi- and tricyclic nucleosides with rather unusual molecular skeletons in a completely regio- and 
stereoselective fashion. When these polycyclic nucleosides were evaluated in cell culture against different classes of viruses, it 
 2   
was found that the tricyclic nucleoside CAM-263 (Figure 1), obtained by reaction of CAM-261 with ethanol at 80 ºC, specifically 
inhibits HIV-1 replication while being inactive against HIV-2 or other (retro) viruses. The good selectivity displayed by CAM-
263 prompted us to perform systematic modifications on this prototype with the objective of determining the minimal structural 
features essential for HIV-1 inhibition. This study form the subject matter of this paper.  
 As a starting point, we focused our attention on the replacement of the ethoxy group at the C-4” position by alkoxy groups of 5 
different length, ramification, conformational freedom or functionalization. In addition, th e ethoxy group has been removed or 
substituted by other functional groups. Next, we studied the role of the tert-butyldimethylsilyl (TBDMS) group at the 2’ position 
by  
 
Fig. 1 Modifications carried out on the tricyclic nucleoside CAM-263 10 
preparing the corresponding 2’-deprotected derivative or by replacing it by other silyl ( tert-hexyldimethylsilyl) or lipophilic 
(acetyl) moieties.   
 Modifications on the nucleobase were also examined. First, the N-3 methyl analog of CAM-263 has been prepared in order to 
determine the importance of H-bond-donating ability of the amide proton at 3-N position of the thymine nucleobase. Finally, the 
thymine of the prototype compound has been replaced by uracil or by an aromatic moiety such as SPh.  15 
 
Results and discussion 
Chemical Synthesis 
We studied first the effect of the substitution of the ethoxy moiety of the prototype compound CAM-263 by flexible alkoxy moieties of 
different length and ramification. These compounds were readily prepared in one step by reaction of CAM-261 with the corresponding 20 
alcohols in refluxing acetonitrile at 80 ºC (Scheme 1).5 Thus, reaction of CAM-261, under reflux, with different primary alcohols such as 
methanol, propanol, butanol, pentanol, isobutyl alcohol and 2,2-dimethyl-1-propanol afforded the corresponding  tricyclic derivatives: 
CAM-286 (58%), the prototype CAM-263 (70%), CAM-300 (60%),5  CAM-3615 (78%), CAM-2935 (79%), CAM-285 (72%) and 
CAM-370 (83%) in high yields (58-83%).  
  
Scheme 1 Synthesis of CAM-xxx to CAM-xxx 
 To study how the conformational restriction of the alkoxy moiety affects in the activity, we prepared compounds CAM-391 (80%) and 
CAM-392 (76%) in which a double or triple bond was present (Scheme 1). On the other hand, the functionalization of the alkoxy moiety 
was studied by preparing compounds CAM-318 (74%) and CAM-295 (67%), with an hydroxy or phenoxy moiety at the terminal end of 5 
the alkoxy moiety, or  compounds CAM-299 (80%) or CAM-316 (67%) with benzyloxy or tetrahydrofuranylmethoxy groups at the C-4” 
position (Scheme 1). These compounds were prepared following a similar procedure to that described for the synthesis of CAM-286-
xxxx. Thus, the reaction of CAM-261 with 2-propen-1-ol, 2-propyn-1-ol, 1,2-ethanediol, 2-phenoxy-1-ethanol, benzyl alcohol and 
tetrahydro-2-furanmethanol in refluxing acetonitrile afforded the corresponding tricyclic nucleosides CAM-391-xxxx  in high yields (67-
80%).  10 
As it was previously determined for the prototype CAM-263,5 the stereochemistry of the new stereogenic center created on C-4” in this 
series of compounds was unequivocally determined as S on the basis of NOE difference experiments. 
Compound CAM-380 in which the ethoxy moiety at the C-4” position has been removed was also prepared (Scheme 1). The synthesis 
of this compound was attempted first by hydrogenation of CAM-261 using 10% palladium on charcoal as catalyst. However, under these 
conditions, the starting compound CAM-261 remained unchanged, even upon prolonged reaction times. Instead, when platinum oxide 15 
was used as catalyst, compound CAM-380 was obtained in 30% yield. 
In compound CAM-380, the signal at δ 4.54 ppm, corresponding to the H-4” proton, correlates with the signal of the H-2’ proton of the 
sugar, at δ 4.90 ppm, indicating that the H-4” proton is on the upper side (β-face) of the furanose ring (Figure 2). This result confirms that 
the conjugate addition of the hydrogen proceeded with complete stereoselectivity on the β-face of the sugar-fused cyclic enamine CAM-
261.  20 
 
Fig. 2 Observed NOE’s for comppunds CAM-380, 5 and 6 
On the other hand, to determine the importance of the ethoxy moiety, we tested the nucleoside analogues CAM-509,6 CAM-354,5 
CAM-3155 and CAM-3215 with hydroxy, ethylthio, cyano and carboxamide moieties at the C-4” position that have been previously 
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synthesized in our laboratory (Figure 3). In addition, the 4”-O-tert-butyldimethylsilyl derivative CAM-536 was prepared in 73% yield by 
treatment of the 4”-hydroxy derivative CAM-509 with tert-butyldimethylsilyl chloride in pyridine at room temperature.  
Next, modifications at the 2’ position was investigated (Scheme 2). Starting from CAM-263 the 2’ deprotected derivative CAM-291 
was obtained in 69% yield by treatment with ammonium fluoride in methanol. Acetylation of CAM-291 using acetic anhydride/pyridine 
afforded the 2’ acetyl derivative CAM-400 in 86% yield. Alternatively, reaction of CAM-291 with tert-hexyl dimethylsilyl chloride in 5 
acetonitrile at room temperature afforded the corresponding 2’-O-silylated nucleoside CAM-589  in xxxx% yield.  
 
 
 
Fig. 3 Structure of compounds CAM-xxx to CAM-xxx 10 
 
Scheme 2 Synthesis of CAM-xxx to CAM-xxx 
With respect to the modifications on the nucleobase the introduction of a methyl group at the N-3 position of the thymine was first 
carried out (Scheme 3). Thus, compound CAM-263 was transformed to the corresponding 3-N-methyl nucleoside CAM-103-2 by 
selective N-3-alkylation using methyl iodide in the presence of potassium carbonate.  15 
Secondly, we prepared compounds CAM-546 and CAM-442 in which the thymine of the prototype has been replaced by uracil or 
thiophenyl moieties (Scheme 4). The synthesis of these compounds consisted on a convergent strategy in which the 5-O-tosyl-3-cyano 
mesyl ribofuranose 37 (Scheme 4) has been employed as a common sugar precursor in glycosylation reactions.  
For the synthesis of 3 our previously described 5-O-tosyl derivative 1  (Scheme 5) has been used.5 Thus, hydrolysis of the 1,2-O-
isopropylidene moiety of 1, with aqueous trifluoroacetic acid, followed by reaction with acetic anhydride/pyridine afforded a 1:1.5 20 
mixture (deduced from 1HNMR spectrum) of the two anomeric forms (α and β) of the diacetate derivative 3 in 90% yield. Condensation 
of 3 with silylated uracil under modified Vorbrüggen8 conditions afforded the 3’-cyano mesyl nucleoside 4 in 58% yield. The coupling 
 constant value J1’,2’ = 7 Hz observed for this compound is in reasonably good agreement with the data for other cyanomesyl nucleosides 
described in our group.9 
On the other hand, reaction of 3 with thiophenol in the presence of boron trifluoride etherate afforded the β aryl thioglycoside 6 in 
62% yield together with the α aryl thioglycoside 5 as a minor compound (1%). In these sugar derivatives the similar values of the 
coupling constant J1,2 observed between the α (J1,2 = 5.9 Hz) and β anomers (J1,2 = 5.8 Hz) precluded its use to establish the anomeric 5 
configuration. Therefore, their anomeric configuration was unequivocally determined by a NOE experiment (Figure 2). Thus, for the 
major  
 
Scheme 3 Synthesis of CAM-103-2 
 10 
 
Scheme 4 Key  glycosylation approach for the synthesis of CAM-546 and CAM-442 
isomer 6, irradiation of H-1 caused enhancement of the signals for H-4 indicating that both protons, H-1 and H-4, are at the lower face (α 
face) of the furanose ring, and therefore the anomeric configuration of this compound is β. For the minor isomer 5, irradiation of H-1 
causes enhancement of the signals H-2 and H-5 indicating that all of these protons are at the upper face (β face) of the furanose ring, and 15 
therefore the anomeric configuration of this compound is α.  
Once the 5’-O-tosyl cyano mesyl nucleoside 4 was obtained, we attempted its transformation into the spiro nucleoside 7 (Scheme 6, 
Path A) following a protocol similar to that previously established for other cyano mesyl nucleosides with a benzoyl, instead of tosyl, 
moiety at the 5’ position of the sugar.9 Thus, treatment. of 4 under non-nucleophilic basic conditions (potassium carbonate/acetonitrile) at 
room temperature afforded the expected spiro derivative 7 in 30% yield, together with an unexpected compound (8) that was formed in 20 
20% yield. Formation of 8 could be explained through the formation of 7 followed by the “in situ” intramolecular attack of the 4”-amino 
group to the tosyl leaving group at the 5’ position of the sugar5 and acetyl group migration from the 2’ position to the NH of the pyrroline 
ring. Compound 8 could be considered as an attractive synthetic intermediate for the synthesis of the desired CAM-546 and for this 
reason we decided to drive the formation of 8 to completion, avoiding the isolation of 7. 
With this aim, the conversion of the starting 5-O-tosyl nucleoside 4 to the desired nucleoside 8 was studied as a function of reaction 25 
time, temperature and base. Among the set of reactions assayed, the best results were obtained when DBU was used as a base, 0 ºC, and 
10 min reaction time. Under these conditions, the clean formation of 7 was detected by TLC analysis (Scheme 6, Path B). On increasing 
the temperature to 80 ºC for 15 extra minutes the reaction goes to completion and compound 7 was consumed. At this time a mixture of 
compounds was detected by TLC from which the desired nucleoside 8 together with its 2’-O-acetyl derivative 9 was identified by NMR. 
Treatment of the mixture with methanol ammonia gave the methoxy derivative 10 in 65% yield. Noteworthy, the reaction of 10 with tert-30 
butyldimethylsilyl chloride and DMAP at 80ºC did not afford the expected uracil nucleoside CAM-546, instead the 4”-O-silylated 
derivative 11 was obtained in xxx% yield.  
 6   
 
Scheme 5 Synthesis of 3-6 
 
 
Scheme 6 Synthesis of compounds 7-11 5 
  
 
Scheme 7 Proposed mechanism for the synthesis of compound 11 
A plausible explanation for the formation of 11 is illustrated in Scheme 7. We propose that, by heating, nucleoside 10 might 
experiment the elimination of methanol to give the cyclic enamine CAM-261. This transformation is consistent with literature data10 that 5 
indicates that the Michael-type addition products (in our case, compound 10) can often be reverted to the starting material by heating. 
Next, the addition of water to the conjugated double bond of CAM-261 (position 4”) might afford the 4”-hydroxy nucleoside 12 that was 
readily silylated.  
To confirm the reversibility of our Michael-type reaction, the 4”-methoxy derivative CAM-286 was reacted with a mixture of 
acetonitrile/water at 80ºC under weak acid media (pH adjusted at 5-6 with acetic acid). Under these conditions the 4”-hydroxy derivative 10 
CAM-509 was obtained confirming our hypothesis (Scheme 7).  
Finally, synthesis of CAM-546 and CAM-442 was undertaken as shown in Scheme 8. Thus, 2’ deprotection of nucleoside 4 with 
saturated methanolic ammonia gave the deprotected nucleoside 13 which was not purified. Reaction of 13 with tert-butyldimethylsilyl 
chloride at 80 ºC for 1 hour afforded the 2’-O-silylated nucleoside 14 (68%). It should be mentioned that the substitution of the 5’-tosyl 
group by chloride was observed upon prolonged reaction times. The 5’-chloro derivative obtained  15 
 
Scheme 8 Synthesis of CAM 546 and CAM 442 
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behaves exactly as the corresponding 5’-O-tosyl derivative 14 and for this reason when the substitution takes place the resulting mixture 
was used directly without purification. Nucleoside 14 was treated with DBU to give the spiro derivative 15 (68%). Reaction of 15 with 
potassium carbonate at 80 ºC for 5 h afforded the cyclic enamine sulfonate 16 in 70% yield that was treated with ethanol to afford CAM-5 
546 in 61% yield.  
A similar synthetic sequence was followed with the thiophenyl  derivative 6 to afford the 2’-O-silylated derivative 18 that was 
transformed into 19 (77%), 20 (73%) and CAM 442 (79%) as described above (Scheme 8).  
Biological evaluation  
Table 1 summarizes the results of the biological evaluation of the test compounds expressed as EC50 values or compound concentrations 10 
required to inhibit virus-induced cytopathicity in CEM and MT-4 cell cultures by 50%. The antiviral data on the prototype compound 
(CAM-263) is also reported as reference.  
Whereas several compounds inhibited HIV-1 replication in the lower micromolar concentration range, none of the compounds proved 
active against HIV-2 at subtoxic concentrations (Table 1). Therefore, the active compounds should be considered as specific inhibitors of 
HIV-1 replication. Their anti-HIV activity in CEM cells were similar than in MT-4 cells. 15 
Nucleosides CAM-286 and CAM-300 with one more or one less carbon atom in the alkoxy chain than the prototype showed an 
antiviral activity comparable to it. However, compounds with longer alkoxy chains (CAM-361 or CAM-293) were devoid of antiviral 
activity. The propyloxy derivative CAM-300 was the most inhibitory to HIV-1 replication in CEM cells of this series. 
The rigidity of the alkoxy moiety seems to influence the antiviral activity. Thus, compounds CAM-391 and CAM-392 with a less 
flexible alkenyl or alkynyl alkoxy chain were inactives. 20 
Table 1  Inhibitory effects of test compounds on HIV-1 and HIV-2 replication in MT-4 and CEM cell culture and recombinant HIV-1 RT 
 EC50 (µM)
[a]
 CC50 (µM)
 [b]
 
CAM 
MT-4 CEM CEM 
HIV-1 HIV-2 HIV-1 HIV-2 HIV1/138K
 [c]
  
286 8.4  3.9 50 5.5   0.7 50 500 111  14.8 
300 5.1  0.4 10 1.4  0.8 10 500 28.5  2.0 
361 10 10 10 10  34.8  13.7 
293 5 5 5 5 500 10.1  0.1 
285 5.2  0.6 10 8.0  2.8 10 500 21.1  3.6 
370 10 10 10 10  21.5  1.6 
391 10 10 15.0  5.0 50  57.8  9.3 
392 25 25 25 25  66.2  4.9 
318 (2) - - 50 50  97.7  4.7 
295 5 5 5 5 500 10.4  0.7 
299 10 10 10 10 500 20.4  1.1 
316 10 10 50 50  72.0  1.7 
380 30.4  23.5 125 30.0  7.1 125  125 
509 250 250 250 250  250 
536 - - 2 2  7.04  1.8 
354 31.1  16.5 50 32.5  3.5 50  80.6  8.6 
314 50 50 50 50  103.0  7.9 
321 125 125 125 125  125 
291 (2) _ _ 250 250  250 
589 _ _ 10 10  27.0  3.6 
400 250 250 250 250  250 
103 (2) 3.6  2.3 50 3.0  1.4 50  32.0  2.0 
546 50 50 50 50  111.0  1.4 
442 - - 10 50  131.0  12.7 
 263 13.8  5.4 10 7.7  4.0 50 500 25.0  1.2 
[a] 50% effective concentration, or the compound concentration required to inhibit HIV-induced cytopathicity by 50%.  
[b] 50% cytostatic concentration, or the compound concentration required to inhibit cell proliferation (CEM) or to reduce cell viability (MT-4) by 50%. 
[c] 50% inhibitory concentration, or the compound concentration required to inhibit recombinant HIV-1 RT activity by 50% 
 
The isobutyloxy derivative CAM-285 showed an antiviral activity comparable to that of the unbranched derivatives. However, an 5 
increase in the number of the branch chain alkyl groups leads to an inactive compound (CAM-370).  
Compounds CAM-318-2 and CAM-295, bearing an ethoxy chain functionalized with a hydroxy or phenoxy moiety, were inactives. 
Compounds CAM-299 and CAM-316 with a methoxy chain functionalized with phenyl or furanyl moieties were also devoid of antiviral 
activity. This observation suggests that the functionalization of the alkoxy chain is not well tolerated. 
Replacement of the ethoxy moiety in the prototype by OH or OTBDMS resulted in compounds (CAM-509, CAM-536) that lack 10 
activity. The presence of other functional groups (CN and CONH2) also gave inactive compounds (CAM-314 and CAM-321). In 
contrast, nucleoside CAM-380 lacking the ethoxy moiety or CAM-354 with an ethyl chain containing a sulfur atom at C-4” were 
endowed with anti-HIV-1 activity, although are approximately 2-fold less actives than the prototype.  
Substitution of the TBDMS group at 2’ position of the ribofuranose by other lipophilic moieties, such as tert-hexyldimethylsilyl 
(CAM-589) or acetyl (CAM-400), gave inactive compounds. The 2’-deprotected derivative (CAM-291-2) was also inactive. 15 
The 3-N-methylthymine derivative CAM-103-2 was 4-fold more active than its unsubstituted counterpart (CAM-263). Substitution of 
the thymine moiety by uracil or SPh gave inactive compounds (CAM-546 and CAM-442) respectively. 
 
Conclusions 
In summary, in this paper we report on novel derivatives of the prototype tricyclic nucleoside CAM-263 by modifying the ethoxy moiety 20 
at the C-4” position, the nucleobase and the substituent at the 2’ position. Several members of this class of compounds show specific 
anti-HIV-1 activity comparable and even slightly superior to those of the prototype tricyclic nucleoside. Our structure-activity 
relationship studies demonstrate that both, the presence of thymine and a tert-butyldimethylsilyl group at the 2’-position of the sugar are 
important structural components since deletion of either of them is detrimental to the anti-HIV-1 activity. Modifications at the alkoxy 
moiety at C-4” position were less stringent to keep anti-HIV-1 activity. Thus, the ethoxy moiety can be replaced by methoxy, propyloxy, 25 
hydrogen and ethylthio moieties. Introduction of a methyl group at the position N-3 of the thymine ring enhanced the antiviral activity by 
4-fold. The tricyclic nucleosides here described represent a novel type of selective anti HIV-1 inhibitors. 
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